GLP-1 Microdosing and High Blood Pressure: What 24-Hour Monitoring and the Dose Data Show
GLP-1 microdosing and high blood pressure come up together for a simple reason: excess weight and hypertension travel as a pair, and GLP-1 medicines lower both. The more useful questions are how far blood pressure falls at the lowest doses that have actually been studied, why it falls, and what that means for anyone who already takes a blood pressure pill.
-7.4
MM HG 24-HOUR SYSTOLIC CHANGE VS PLACEBO ON TIRZEPATIDE 5 MG, THE LOWEST DOSE IN SURMOUNT-1
-4.95
MMHG SYSTOLIC DIFFERENCE VS PLACEBO ON SEMAGLUTIDE 2.4 MG ACROSS 3,136 PARTICIPANTS
70%
SHARE OF THE TIRZEPATIDE SYSTOLIC DROP STATISTICALLY EXPLAINED BY WEIGHT CHANGE
Most people start a GLP-1 for weight or blood sugar. Blood pressure tends to show up later, at a routine check, when the reading is lower than it has been in years. Sometimes it shows up as a lightheaded moment on standing, which is the less welcome version of the same effect.
This article draws on the SURMOUNT-1 24-hour monitoring substudy, a pooled analysis of the semaglutide weight trials, three meta-analyses published between 2025 and 2026, a dulaglutide mediation analysis and a 2026 mouse study on mechanism. One limit applies throughout: none of these studies tested sub-label microdose protocols. The lowest doses with real blood pressure data are tirzepatide 5 mg and semaglutide in its standard range. Anything below that is unmeasured.
Key takeaways
- •In the SURMOUNT-1 ambulatory monitoring substudy, tirzepatide lowered 24-hour systolic blood pressure by 7.4, 10.6 and 8.0 mm Hg versus placebo on 5, 10 and 15 mg at week 36.
- •The lowest tirzepatide dose delivered most of the systolic effect of the highest dose, so the blood pressure response does not scale neatly with dose.
- •Semaglutide 2.4 mg lowered systolic pressure by 4.95 mmHg versus placebo in a pooled analysis of 3,136 people, with a similar 4.78 mmHg drop in those with hypertension.
- •Weight loss explains most of the drop, about 70% in SURMOUNT-1, but dulaglutide data and mouse studies point to an additional direct effect on blood vessels and the kidney.
- •A 2026 meta-analysis of 32 trials linked tirzepatide to more hypotension-related events (risk ratio 2.45), which matters most for people already on blood pressure medicine.
Does GLP-1 microdosing lower high blood pressure?
GLP-1 medicines lower high blood pressure at every standard dose that has been tested, but blood pressure at true microdoses has never been measured in a trial. The best low-dose evidence comes from tirzepatide 5 mg, the lowest of the three doses in SURMOUNT-1. On that dose, 24-hour systolic pressure fell 7.4 mm Hg more than on placebo.
That number comes from the most rigorous kind of blood pressure measurement. De Lemos and colleagues reported a prospectively planned substudy in Hypertension in 2024. The substudy enrolled 600 SURMOUNT-1 participants whose blood pressure was under 140/90, and 494 of them had valid 24-hour monitoring at baseline and week 36. Readings were taken every 30 minutes by day and every hour at night.
Tirzepatide: change in 24-hour ambulatory blood pressure versus placebo at week 36 (mm Hg)
de Lemos JA et al., Hypertension 2024. SURMOUNT-1 ambulatory monitoring substudy, adults with BMI 27 or higher, no diabetes.
- Systolic
- Diastolic
Look at the shape rather than the peak. The 5 mg dose captured most of the systolic effect, 10 mg went a little further, and 15 mg landed between them at 8.0 mm Hg. Diastolic pressure fell 2.0 mm Hg on 5 mg and 2.9 mm Hg on 10 mg, but the 0.5 mm Hg change on 15 mg was not significant. For people interested in lower doses, that flat curve is the most relevant finding in the paper, with the caveat that 5 mg is still a full approved dose and not a microdose.
Why does 24-hour monitoring matter more than a clinic reading?
Ambulatory monitoring matters because it captures blood pressure across a whole day and night instead of one tense moment in a clinic. The SURMOUNT-1 authors note that nighttime systolic pressure is a stronger predictor of cardiovascular and all-cause death than daytime or 24-hour averages. Tirzepatide lowered nighttime pressure as well as daytime pressure at each dose.
The substudy also checked whether the effect depended on who was taking the drug. Baseline 24-hour systolic pressure averaged 124.6 mm Hg, 30.0% of participants reported hypertension and 29.0% used at least one blood pressure medicine. The reduction held across age, sex, BMI, baseline systolic pressure, hypertension status and antihypertensive use. In other words, the drop was not confined to the people with the highest readings.
How much does semaglutide lower blood pressure in people with hypertension?
Semaglutide lowers systolic blood pressure by roughly 5 mmHg in people with hypertension, about the same as in everyone else. Kennedy and colleagues pooled individual patient data from three 68-week trials of semaglutide 2.4 mg in the European Heart Journal in 2024, covering 3,136 participants.
Semaglutide 2.4 mg: systolic blood pressure change versus placebo, by subgroup (mmHg)
Kennedy C et al., Eur Heart J 2024. Individual patient data from three 68-week trials.
The overall difference was -4.95 mmHg. In people with a hypertension diagnosis it was -4.78 mmHg, in those starting above 130 it was -4.93 mmHg, and above 140 it was -4.09 mmHg. In apparent resistant hypertension the estimate was -3.16 mmHg, with a wide interval that crossed zero. The authors add an important detail: antihypertensive treatment intensity fell on semaglutide compared with placebo, by a score of -0.51. Some of the true blood pressure effect was therefore hidden, because doctors were removing pills as readings improved.
What about lower semaglutide doses? A meta-analysis of 20 trials by Ala and Moheb Aleaba in the Journal of Endocrinological Investigation found an average drop of 3.71 mmHg systolic and 1.10 mmHg diastolic. The effect was larger at doses above 1 mg per week and with weight loss beyond 10 kg. That hints at a dose gradient for semaglutide, though not one that has been tested at microdose levels. Our breakdown of low dose semaglutide, dose by dose covers the weight side of that picture.
Do dual and triple agonists lower blood pressure more than semaglutide?
Yes, on average the newer multi-receptor drugs lower blood pressure more than single GLP-1 agonists. Basile and colleagues pooled 85 randomized trials and 90,977 participants for the European Journal of Preventive Cardiology in 2026. GLP-1 agonists lowered office systolic pressure by 3.4 mmHg, dual agonists such as tirzepatide by 5.1 mmHg and triple agonists by 6.6 mmHg.
Office blood pressure reduction versus placebo, by drug class (mmHg)
Basile C et al., Eur J Prev Cardiol 2026. Meta-analysis of 85 randomized trials in adults with overweight or obesity.
- Systolic reduction
- Diastolic reduction
Greater weight loss tracked with a greater fall in blood pressure across those trials, which explains much of the ranking. Diastolic changes were modest everywhere, topping out at 2.1 mmHg for triple agonists. These are averages across full treatment doses, so they describe the ceiling rather than what a low-dose protocol is likely to do.
Is the blood pressure drop only from weight loss?
Weight loss is the main driver of the blood pressure drop on GLP-1 medicines, but it does not seem to be the whole story. In SURMOUNT-1, change in 24-hour systolic pressure correlated with change in body weight (r=0.31), and mediation analysis attributed about 70% of the effect to weight. The authors also suggest tirzepatide may act on blood pressure independently of weight.
Dulaglutide offers a cleaner look, because it causes less weight loss. Ferdinand and colleagues ran a mediation analysis across the AWARD placebo-controlled trials in people with type 2 diabetes for Cardiovascular Diabetology in 2023. Dulaglutide 1.5 mg lowered systolic pressure by 2.6 mmHg, and 64% of that effect was independent of weight.
Dulaglutide 1.5 mg: where the systolic blood pressure drop came from (mmHg)
Ferdinand KC et al., Cardiovasc Diabetol 2023. Mediation meta-analysis of placebo-controlled AWARD trials, type 2 diabetes.
Where might the weight-independent part come from? A 2026 study by Medak and colleagues in JCI Insight found that, in mice, GLP-1 receptors on the smooth muscle of artery walls were required for semaglutide to lower blood pressure. The same receptors were needed for semaglutide to increase sodium excretion by the kidney, and semaglutide relaxed isolated arteries directly. These are mouse findings and explain mechanism, not human outcomes. They do make it plausible that a GLP-1 dose too small to move the scale much could still nudge blood pressure, though no human trial has tested that idea.
Can a GLP-1 make blood pressure too low?
A GLP-1 can push blood pressure too low, and the risk is clearest with tirzepatide. Chen and colleagues pooled 32 randomized trials and 47,332 participants in Endocrine in 2026. Tirzepatide cut the risk of hypertension-related adverse events (risk ratio 0.40) but raised hypotension-related events (risk ratio 2.45), rising to 2.58 at higher doses.
Risk ratios for blood pressure adverse events versus comparators
Chen QX et al., Endocrine 2026. Meta-analysis of 32 trials. A value of 1 means no difference; semaglutide results were not statistically significant.
- Hypertension events
- Hypotension events
Semaglutide looked neutral in the same analysis, with risk ratios of 0.81 for hypertension events and 1.39 for hypotension events, neither statistically significant. The practical risk sits with people whose blood pressure is already controlled by medicine. When the drug lowers pressure and the pills keep working at full strength, readings can drift too low, and that can feel like dizziness on standing, fatigue or a washed-out afternoon.
Dehydration from reduced eating and drinking can add to this in the first weeks. Our article on headaches, dizziness and blood pressure on a GLP-1 microdose walks through the lightheaded phase in more detail, and the piece on GLP-1 medication interactions covers other drugs worth reviewing.
Why does heart rate rise while blood pressure falls?
A small rise in resting heart rate is an expected GLP-1 effect and often eases over time. In the SURMOUNT-1 monitoring substudy, baseline heart rate averaged 77.4 beats per minute. At week 36 it rose 2.1, 2.3 and 5.4 beats per minute versus placebo on 5, 10 and 15 mg.
Tirzepatide: heart rate change by dose (beats per minute)
de Lemos JA et al., Hypertension 2024. Week 36: ambulatory difference versus placebo. Week 72: change from baseline in the main trial (placebo 0.1).
- Week 36
- Week 72
By week 72 of the main trial, pulse changes from baseline were 0.6, 2.3 and 2.6 beats per minute, compared with 0.1 on placebo. On the lowest dose, the rise had almost disappeared. Anyone tracking this on a smartwatch will find more context in our guide to resting heart rate and HRV on a GLP-1 microdose.
Is a 5 to 10 point drop worth caring about?
A 5 to 10 point drop in systolic pressure is clinically meaningful. The Blood Pressure Lowering Treatment Trialists' Collaboration analysed 48 randomized trials and 344,716 people in The Lancet in 2021. Each 5 mm Hg reduction in systolic pressure carried a hazard ratio for major cardiovascular events of 0.91 in people without prior cardiovascular disease and 0.89 in those with it.
Those trials used blood pressure drugs, not GLP-1 medicines, so the benefit cannot simply be transferred. But it explains why cardiologists pay attention to a few millimetres of mercury. For the wider cardiovascular picture, including cholesterol and outcome trials, see our article on GLP-1 microdosing and heart health.
What should someone on blood pressure medicine track on a GLP-1 microdose?
Someone on blood pressure medicine should track home readings and symptoms, and share both with the prescriber rather than adjusting pills alone. The trial data show blood pressure can fall within months on standard doses, and the semaglutide trials show clinicians reduced antihypertensive treatment as it did. A low-dose protocol may move more slowly or less, but nobody has measured it.
- •Take a few baseline home readings before starting, at the same time of day, seated and rested.
- •Keep a simple log of morning and evening readings for the first weeks, and note any lightheadedness on standing.
- •Bring the log to appointments. Readings that keep falling, or symptoms of low pressure, are a reason to review medicine doses with the prescriber.
- •Stay hydrated, especially on days when appetite and fluid intake are low.
The lowest studied tirzepatide dose did most of the blood pressure work of the highest. That is encouraging for lower doses, but it is a reason to watch readings closely, not a reason to drop blood pressure pills.
Frequently asked questions
Does microdosing a GLP-1 lower blood pressure?
GLP-1 medicines lower blood pressure at standard doses, but no trial has measured blood pressure at sub-label microdoses. The lowest dose with good data is tirzepatide 5 mg, which cut 24-hour systolic pressure by 7.4 mm Hg versus placebo in the SURMOUNT-1 monitoring substudy. Whether smaller doses do the same is not established.
How much does tirzepatide lower blood pressure?
In the SURMOUNT-1 ambulatory monitoring substudy, tirzepatide lowered 24-hour systolic blood pressure by 7.4, 10.6 and 8.0 mm Hg versus placebo on 5, 10 and 15 mg after 36 weeks. The drops held during both day and night. Diastolic pressure fell by 2.0 and 2.9 mm Hg on 5 and 10 mg, with no significant change on 15 mg.
How much does semaglutide lower blood pressure?
An individual patient data meta-analysis of three semaglutide 2.4 mg trials found systolic pressure fell 4.95 mmHg more than on placebo. People with diagnosed hypertension saw a similar drop of 4.78 mmHg. A broader meta-analysis of 20 trials put the average at 3.71 mmHg systolic and 1.10 mmHg diastolic.
Is the blood pressure drop just from losing weight?
Weight loss explains most of the drop but probably not all of it. In SURMOUNT-1, about 70% of the ambulatory systolic change was statistically mediated by weight change. In dulaglutide trials, 64% of a 2.6 mmHg drop was independent of weight, and mouse work points to GLP-1 receptors in artery wall muscle as one route.
Can a GLP-1 make my blood pressure too low?
It can, especially for people already taking blood pressure medicine. A 2026 meta-analysis of 32 trials found tirzepatide raised the risk of hypotension-related events, with a risk ratio of 2.45, and more so at higher doses. Semaglutide showed no significant hypotension signal in the same analysis.
Should I stop my blood pressure pills when I start a GLP-1?
No, not on your own. Any change to blood pressure medicine should be made with the prescriber, guided by home readings. In the semaglutide trials, antihypertensive treatment intensity fell compared with placebo, which shows clinicians did step medicines down as pressure improved.
Why does my heart rate go up on a GLP-1?
A small rise in resting heart rate is a known GLP-1 effect. In the SURMOUNT-1 monitoring substudy, heart rate rose 2.1, 2.3 and 5.4 beats per minute versus placebo at week 36 on tirzepatide 5, 10 and 15 mg. By week 72 the change on 5 mg was 0.6 beats per minute, suggesting it can ease with time.
How big a blood pressure drop actually matters?
Smaller drops than people expect. A Lancet analysis of 48 trials and 344,716 people found every 5 mm Hg fall in systolic pressure carried a hazard ratio of 0.91 for major cardiovascular events in people without prior heart disease. That is why a 5 to 10 point drop on a GLP-1 is worth tracking.
Clinical references
- de Lemos JA, Linetzky B, le Roux CW, et al. Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy. Hypertension. 2024. doi:10.1161/HYPERTENSIONAHA.123.22022
- Kennedy C, Hayes P, Cicero AFG, et al. Semaglutide and blood pressure: an individual patient data meta-analysis. European Heart Journal. 2024. doi:10.1093/eurheartj/ehae564
- Chen QX, Zhou XY, Wu Q, et al. Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis. Endocrine. 2026. doi:10.1007/s12020-026-04757-7
- Ala M, Moheb Aleaba M. The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression. Journal of Endocrinological Investigation. 2025. doi:10.1007/s40618-024-02459-3
- Basile C, Merolla A, Mancusi C, et al. Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis. European Journal of Preventive Cardiology. 2026. doi:10.1093/eurjpc/zwaf560
- Ferdinand KC, Dunn J, Nicolay C, et al. Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes. Cardiovascular Diabetology. 2023. doi:10.1186/s12933-023-01775-x
- Medak KD, Koehler JA, Baggio LL, et al. Semaglutide reduces murine blood pressure through the vascular smooth muscle GLP-1 receptor. JCI Insight. 2026. doi:10.1172/jci.insight.201148
- Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. The Lancet. 2021. doi:10.1016/S0140-6736(21)00590-0
Medical disclaimer. This article is for general educational and informational purposes only. It is not medical advice and not a substitute for the clinician or pharmacist responsible for your care. Sub-label "microdose" regimens of GLP-1 medicines have not been tested in clinical trials, and the blood pressure figures quoted here come from standard approved doses. Charts show values reported in the cited studies. Do not start, stop or change blood pressure medicine without your prescriber. Seek urgent care for fainting, chest pain, severe headache or sudden weakness.